OBJECTIVE: To describe the characteristics and outcomes of a cohort of patients with oral vascular anomalies (OVA) treated with sclerotherapy using 5% ethanolamine oleate at a dosage of 0.1 mL per 10 mm of lesion size. STUDY DESIGN: Sixty-seven patients were selected from a review of 300 medical records of individuals who had been diagnosed with OVA. Clinicodemographic characteristics and treatment outcomes were analyzed descriptively and analytically. RESULTS: The overall mean number of sclerotherapy sessions required for clinical healing was 1.1, with lesions up to 6 mm typically requiring only one session. The mean volume of 5% ethanolamine oleate administered was 0.1 mL
however, 97.1% of lesions up to 6 mm were successfully treated with a maximum dose of 0.05 mL. Patients with papular lesions had a significantly lower rate of clinical healing compared to those with macular lesions (OR=0.79
[0.64-0.96]
p=.021). The average time to clinical healing was 16.0 days, with lesions up to 6 mm generally healing within 14 days. Complete clinical healing was achieved in 65.7% of cases. CONCLUSIONS: The low-dose sclerotherapy protocol using 5% ethanolamine oleate is effective for treating OVA, particularly for lesions measuring up to 6 mm in diameter.